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    Abstract 
 
Purpose. Neuroblastoma is a rare childhood cancer whose high risk, 
metastatic form has a dismal outcome in spite of aggressive therapeutic 
interventions. The toxicity of drug treatments is a major problem in this 
paediatric setting. In this study, we investigated whether Polyphenon E, a 
clinical grade mixture of green tea catechins under evaluation in multiple 
clinical cancer trials run by the NCI, has anticancer activity in mouse models 
of neuroblastoma. 
Experimental design. We used three neuroblastoma models: a) transgenic 
TH-MYCN mouse developing spontaneous neuroblastomas b) NOD/SCID 
mice xenotransplanted with human SHSY5Y cells c) A/J mice transplanted 
with syngeneic Neuro 2A cells. Mice were randomized in control and 
Polyphenon E-drinking groups. Blood from neuroblastoma patients and 
normal controls was used to assess phenotype and function of myeloid cells. 
Results. Polyphenon E reduced the number of tumour infiltrating myeloid 
cells, and inhibited the development of spontaneous neuroblastomas in TH-
MYCN transgenic mice.  In therapeutic models of neuroblastoma in A/J, but 
not in immunodeficient NOD/SCID, mice Polyphenon-E inhibited tumour 
growth by acting on myeloid derived suppressor cells (MDSC) and CD8 T 
cells.  In vitro, Polyphenon E impaired the development and motility of MDSCs 
and promoted differentiation to more neutrophilic forms through the 67 kDa 
laminin receptor signalling and induction of G-CSF. The proliferation of T cells 
infiltrating a patient metastasis was re-activated by Polyphenon E.  
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Conclusions. These findings suggest that the neuroblastoma-promoting 
activity of MDSCs can be manipulated pharmacologically in vivo and that 
green tea catechins operate at least in part through this mechanism.  
Translational relevance. In spite of its low frequency, neuroblastoma is a 
malignancy that accounts for 15% of all oncological childhood deaths. Current 
treatments include heavy chemotherapy, radiation and surgery, which often 
cause long lasting adverse effects. Polyphenol E is an orally available, clinical 
grade catechin formulation, which in adult clinical trials has shown no toxicity 
or adverse effects. In this study, we show that the catechin mixture 
significantly inhibits tumourigenesis in mouse models of neuroblastoma by 
inactivating cancer-induced suppressive myeloid cells. Polyphenol E caused 
maturation of myeloid cells, inhibition of their immunosuppressive effects and 
reactivation of patient’s intratumoural T cells. These results suggest that oral 
administration of Polyphenon E could be particularly useful to enhance the 
efficacy of cancer immunotherapy. Specifically, we predict that Polyphenon E 
should augment the antitumour immune response in neuroblastoma patients 
injected with therapeutic antibodies targeting the GD2 molecule. The 
observation that Polyphenol E significantly reduces spontaneous 
tumourigenesis in TH-MYCN mice indicates that the formulation could also be 
used to prevent recurrence after cancer remission induced by standard 
therapies.  
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Introduction 
 
Green tea has been used for thousands of years in traditional Chinese 
medicine to treat human disease. Epidemiologic data demonstrates that Asian 
populations that consume significant quantities of green tea show a reduced 
incidence of cancer (1). Green tea catechins are natural polyphenolic 
formulations endowed with anti-oxidant and anti-cancer activity. In recent 
years a number of reports have shown that green tea catechins inhibit tumour 
proliferation and induce tumour cell apoptosis in vivo and in vitro (2).  A small 
placebo-controlled randomized study in subjects with high-grade prostate 
intraepithelial neoplasia showed that there was a significant reduction in the 
development of prostate cancer in patients taking 600 mg catechins per day 
(3).  Therapeutic concentrations may be achieved by accumulation in target 
tissues, but are associated with minimal toxicity during prolonged treatments 
(1, 3, 4). The mechanisms of action have not been clarified, although it has 
been proposed that catechins modulate key molecular drivers of cell 
proliferation and survival, including cyclin D1 (5). Polyphenon E is a green tea 
catechin formulation, which has been shown to prevent tumourigenesis in 
cancer clinical trials (3, 5-7). To further explore efficacy and mechanism, 
Polyphenon E was supplemented in the drinking water (0.3% w/v) of 
neuroblastoma prone TH-MYCN transgenic mice (8). Unexpectedly, we found 
that the anti-cancer effects of Polyphenon E could be mediated by the 
immune system. 
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Materials and Methods 
 
Reagents. Polyphenon E was kindly provided by Andrew Munro, Polyphenon-
pharma NY, USA. Polyphenon E contains  53% EGCG, 9% epicatechin, 11% 
(−)-epigallocatechin, 5% epicatechin-3-gallate, and 5% (−)-gallocatechin 
epicatechin, 0.55 μg/mL (−)-epigallocatechin, and 0.25 μg/mL (−)-
gallocatechin gallate. The same batch of the formulation was used throughout 
this study. The Polyphenol E powder was dissolved into 100 ml of drinking 
water freshly prepared every other day.  
 
Cell lines. The human neuroblastoma cell line SH-SY5Y was obtained from 
the American Type Culture Collection (ATCC), mouse neuroblastoma Neuro 
2A cells were kindly provided by Dr. Steven Hart, Institute of Child Health and 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 4500 mg/l glucose, 10% foetal calf serum and 2mM glutamine and 1% 
penicillin/streptomycin. Primary mouse neuroblastoma cells were isolated 
from tumour emerging from MYCN mice and cultured in vitro for several 
passages in Roswell Park Memorial Institute Medium 1640 (RPMI) 
supplemented with 20% FCS, 2 mM l-glutamine, 0.1 mM 2-mercaptoethanol, 
1 mM sodium pyruvate, 1× nonessential amino acids and 1% 
penicillin/streptomycin.  
 
Isolation of human neuroblastoma cells from tumour 
A surgically resected human neuroblastoma metastasis was briefly washed in 
PBS, mechanically dispersed and passed through 70μm cell strainer (BD 
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Biosciences) to obtain single-cell suspension. To obtain the cell line growing 
as monolayer cells were plated in 25ml tissue culture flasks and cultured in 
RPMI 1640 medium (supplemented with 20% FCS, 2 mM l-glutamine, 0.1 mM 
2-mercaptoethanol, 1 mM sodium pyruvate, 1× nonessential amino acids and 
1% penicilin/streptomycin solution). FACS analysis with a GD-2 antibody 
showed that >90% of cells were positive to this neuroblastoma antigen.   
 
Mouse bone marrow cultures and generation of MDSCs by co-culture with 
neuroblastoma cells. Bone marrow samples (BM) were harvested from the 
femurs and tibias of 8 weeks old C57Bl/6 (Ly5.2) or A/J mice. Total BM cells 
were maintained in StemSpan serum-free medium (StemCell Technologies) 
supplemented with 1% penicillin/streptomycin and full cytokine cocktail (100 
ng/ml mSCF, 100 ng/ml mFlt3L, 100 ng/ml hIL-11, 20 ng/ml mIL-3).  To obtain 
bone marrow-derived MDSCs, 2.5x105/ml cells were plated into 6 well plates 
(Falcon, BD, NJ, USA) either in RPMI plus 20% FCS supplemented with GM-
CSF (40 ng/ml) and IL-6 (40 ng/ml) cytokines or in conditioned medium from 
neuroblastoma cells derived from tumours isolated from MYCN mice and 
cultured for 3-4 days until confluent. The neuroblastoma condition medium 
was used fresh or defrosted after storage at -80 C. Cells were maintained at 
37°C in 5% CO2-humidified atmosphere for 4 days before FACS analysis. For 
y 1 and 3. 
  
Isolation of mouse and human T cells. We isolated CD3+ T cells from the 
spleens of 8 weeks old C57BL/6 mice via positive selection by using CD3 
isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany). Neutrophils and 
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MDSC subset isolation was carried out by staining the cells with APC -Ly6G, 
PE-CD11B and FITC-Ly6C conjugated antibodies (all from BD, Oxford, UK) 
and FACS sorting. Purity of cell populations was evaluated by flow cytometry 
and exceeded 95%. Human PBMC cells were isolated from the blood or 
disaggregated tumour cells using FICOLL-Hypaque. MDSC- free PBMC were 
obtained by negative selection using a FITC conjugated CD66b primary 
antibody (BD, Oxford, UK) followed by an anti FITC microbeads. All 
separations were performed using Miltenyi Biotec kits and MidiMacs columns. 
Human PBMC and murine CD3+ splenocytes were activated for 5 days with 
antiCD3/28 beads (Dynabead) at a 1:1 ratio (cells: beads) following 
manufacturer protocol (T cell activation/expansion KIT Miltenyi Biotec). 
Regulatory T cells (TREG) were detected by FACS analysis using a kit, 
following manufacturer’s protocol (eBioscience Inc. San Diego, CA, USA). 
Interferon gamma release was measured by ELISA after mixing CD3+ cells 
with monocytic or granulocytic MDSCs (T-cells/MDSCs = 2:1), which were 
washed after culture for 4 days with Polyphenon E-containing, or control, 
medium. Antibodies used for blocking experiments were: 67kDa Laminin, 
clone MLuC5 (Abcam, Cambridge, UK) and an isotype IGM control (Santa 
Cruz, CA, USA); G-CSF, IL-6 and rat IgG isotype control (Abcam, Cambridge, 
UK).  
 
Mouse models of neuroblastoma. Mice of the CBA background with 
expression of human MYCN in the neuroectoderm, prone to develop 
neuroblastomas, were given 0.3% Polyphenon E  in the drinking water. We 
observed that tumour penetrance in this background is 100%, whereas in 
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other mixed backgrounds is significantly reduced (9). Emerging tumours were 
dissected and snap-frozen in liquid nitrogen for subsequent analysis. SCID 
mice (CB17/ICR-Prkdcscid/IcrCrl) were purchased from Charles River. Mice 
were subcutaneously injected into both flanks with 1x106 neuroblastoma cells. 
Polyphenon E (0.3%) was supplemented in the drinking water to half of the 
injected mice starting from the day of tumour injections. A/J mice were 
purchased from Charles Rivers. Tumour size was monitored with a calliper 
and calculated according to the formula: V=(length x width2)/2. 
Immunodepletions were carried out by intra-
antibody/mouse at -1, +3, +7, +15 days from tumour injections. The 
antibodies used for immunodepletion (CD4, CD8 and isotype control) were 
purchased from Bioxcell, West Lebanon, NH, USA.   
 
Immunohistochemistry and FACS staining. Frozen sections were cut, air-dried 
and fixed in 4% paraformaldheyde in PBS. After fixation, sections were 
washed several times in PBS followed by blocking with 5% horse serum in 
PBS and overnight incubation with rat anti-mouse CD11b antibody (BD 
Pharmingen) or rat anti-mouse GR-1 (Bioscience) in a humidified chamber at 
4oC. We used a two-step detection with biotin conjugated anti-rat antibody 
followed by Cy2 conjugated Streptavidin (both from Jackson 
Immunoresearch). For FACS staining, tumours were disaggregated in PBS 
cell lysis prior to incubation with antibodies. 
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Statistical analysis. Kaplan-Meier surviving curves and log-rank test were 
used to compare the survival of TH-MYCN mice treated with Polyphenon E. 
All other results are presented as mean values ± SE and the significance 
calculated using Student’s T test.  
 
Results  
 
The anti-cancer activity of Polyphenon E in mouse models of neuroblastoma 
requires the immune system and is associated with impaired infiltration of 
myeloid cells 
There was a significant decrease in tumour development in TH-MYCN 
transgenic mice exposed to oral catechins, with approximately half of mice 
free from tumour after 8 months, compared with complete tumour penetrance 
in control mice (figure 1a). Interestingly, tumour cells derived from TH-MYCN 
mice were only killed in vitro by concentrations of Polyphenon E that were 
considerably higher than plasma concentrations in rodents drinking up to 
0.5% of Polyphenon E, suggesting that the effects could not be directly 
mediated (10, 11) (figure 1b). Similarly, although SHSY5Y human 
neuroblastoma cells were sensitive to Polyphenon E in vitro (IC50 
figure S1), it did not impair their growth when engrafted in immunodeficient 
SCID mice (figure 1c). We therefore speculated that the anticancer effects of 
Polyphenon E were mediated through augmentation of cellular immunity. 
Gene expression analysis in the emerging tumours indicated that myeloid 
markers such as Cd11b and Gr-1 were downregulated in mice drinking 
Polyphenon E (data not shown). The induction of myeloid derived suppressor 
cells (MDSCs) was recently identified as an important tumour evasion 
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mechanism (12). To visualise myeloid cells infiltrating developing 
neuroblastomas in TH-MYCN transgenic mice, we immunostainined tumours 
emerging from the different treatment groups. There was a significant 
decrease in cells bearing the myeloid markers CD11b or Gr-1 in Polyphenon 
E-drinking mice, suggesting that the green tea formulation inhibits tumour 
infiltrating myeloid cells (figure 1d). To confirm this hypothesis in a therapeutic 
model of neuroblastoma with a proficient immune system, A/J mice were 
administered Polyphenon E orally and injected subcutaneously with 
syngeneic Neuro 2A cells. Polyphenon E-drinking mice showed a significant 
inhibition of tumour growth compared to control mice (figure 2a). This result 
confirmed that Polyphenon E is able to reduce tumour growth in therapeutic 
as well as prophylactic settings, and that this effect is dependent on functional 
cellular immunity. Enumeration by flow cytometry showed that CD11b/Gr-1 
double positive myeloid cells were generally less abundant in the tumours and 
lymphoid organs of Polyphenon E drinking mice, compared to control animals 
(figure 2b). This was accompanied by a significant and robust increase of 
single positive CD4 and double positive CD4/CD8 T cells infiltrating the 
tumours of Polyphenon E drinking mice, compared to control mice (figure 2c). 
Of note, nonconventional double positive T cells have been detected in 
cancer patients and display cytotoxic activity against myeloma and 
melanoma, the latter tumour sharing with neuroblastoma a neuroectodermal 
origin (13-15) 
 
Promotion of neuroblastoma growth in vivo by tumour-induced myeloid cells is 
antagonized by Polyphenon E, which requires the activity of CD8 T cells 
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To assess the role of myeloid cells in tumour growth in this setting, we co-
injected Neuro 2A cells with bone marrow cells derived from A/J mice and 
cultured in the presence of neuroblastoma supernatants (to induce MDSCs) 
with or without Polyphenon E. After 5 days in culture, these cells were about 
90% positive for the CD11b marker (data not shown).  We observed a 
significant and large increase of tumour volumes in mice co-injected with 
myeloid cells, compared to mice injected with neuroblastoma cells alone. Of 
note, the tumour promoting effect was completely abolished if myeloid cells 
had been cultured with Polyphenon E before injection (figure 3a). We 
detected an increase of infiltrating T cells in tumours co-injected with 
Polyphenon E-treated MDSCs (figure S1a), and immune depletion of CD8, 
but not CD4, T cells resulted in enhanced tumour growth on administration of 
Polyphenon E-treated MDSCs. This observation is consistent with CD8 cells 
being required for the host response against tumour that is liberated by the 
Polyphenon E suppression of MDSC activity (figures 3b and S1b). Thus, we 
conclude that Polyphenon E-mediated inhibition of MDSCs tumourigenic 
activity requires CD8 T cells.   
 
Polyphenon E promotes differentiation of immature myeloid cells via activation 
of the 67kDa laminin receptor and secretion of G-CSF 
To investigate in more detail whether green tea catechins affect the growth 
and/or development of MDSCs, we cultured neuroblastoma–induced MDSCs 
(Figure S2) in the presence or absence of 5g/ml of Polyphenon E, a 
concentration that is not toxic to transformed or normal human and mouse cell 
lines in vitro (figure 1b and figures S3 and S4). In the presence of Polyphenon 
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E, there was a decrease in the number of cells with a monocytic phenotype 
(CD11b+ve/Ly6G-ve/Ly6Chigh), whereas cells bearing granulocytic markers 
(CD11b+ve/Ly6G+ve/Ly6Clow) were increased in number, suggesting that 
the catechin formulation could induce a change in the phenotype of MDSCs 
(figure 4a). Consistent with these observations, unsorted myeloid cells from 
bone marrow cells cultured for 4 days in neuroblastoma supernatants and 
exposed to Polyphenon E were morphologically more differentiated than 
vehicle treated cells, with many cells displaying multilobed nuclei 
characteristic of mature neutrophils (figure 4b). When we separated by FACS 
sorting the cells with monocytic (CD11b+ve/Ly6G-ve/Ly6Chigh) or 
granulocytic (CD11b+ve/Ly6G+ve/Ly6Clow) markers, their morphology was 
consistent with the molecular markers and Polyphenon E appeared to mainly 
promote morphological differentiation of granulocytic MDSCs (figure S5). Of 
note, myeloid cells with monocytic markers migrated towards neuroblastoma 
cells in a transwell assay significantly better than cells with granulocytic 
markers, suggesting that Polyphenon E, by shifting the balance towards a 
granulocytic phenotype, could also hinder the migration of MDSCs at tumour 
sites (figure 4c).  
 
A major component of Polyphenon E is epigallocatechin 3-gallate (EGCG), 
which has been shown to affect cell signalling via interaction with the 67-kDa 
laminin receptor (11). We investigated whether this receptor was involved in 
polyphenon E signalling by culturing bone marrow cells in the presence or 
absence of a blocking antibody or an isotype-matched control.  The specific 
antibody completely reversed the changes in molecular markers induced by 
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the catechins, demonstrating that the 67kDa laminin receptor signalling is 
required for the differentiating activity of Polyphenon E (figure 4d).  
We next investigated a potential mechanism for how Polyphenon E altered 
the differentiation of myeloid cells.  We separated by FACS sorting the 
monocytic or granulocytic MDSCs obtained after culturing bone marrow cells 
with neuroblastoma supernatants, with or without Polyphenon E. Next, we 
assessed secretion of cytokines using a commercial array. While Polyphenon 
E did not induce increased secretion of cytokines in granulocytic MDSCs 
(data not shown), three cytokines were sharply up-regulated in monocytic 
MDSCs: IL-16, G-CSF and IL-6 (figure S6, panel a). We focused our attention 
on G-CSF and IL-6, since these cytokines were previously shown to be 
important for differentiation and proliferation of myeloid cells (16, 17). We 
validated the Polyphenon E-induced secretion of the G-CSF and IL-6 by 
ELISA (not shown). Blocking antibodies directed against G-CSF, but not IL-6, 
reverted the effect of Polyphenon E on myeloid cell maturation, causing an 
accumulation of monocytic MDSCs and a concurrent decrease of cells with a 
granulocytic phenotype (figure S6 panels b,c).  
 
Polyphenon E antagonizes the immunosuppressive activity of myeloid cells 
To assess whether catechins not only affected the differentiation but also the 
immunosuppressive activity of myeloid cells, we separated vehicle or 
Polyphenon E treated monocytic MDSCs (CD11b+/Ly6G-ve/Ly6Chigh) by 
flow cytometric sorting, and mixed them with CD3+ splenic T lymphocytes. 
Secretion of interferon gamma (IFN-) was determined after stimulation with 
anti-CD3 and anti-CD28 antibodies. As expected, monocytic MDSCs 
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drastically reduced the release of IFN- by T cells.  However, there was a 
large and significant rescue of IFN- secretion when MDSCs were pre-treated 
with Polyphenon E (figure 5a). Similar results were observed using 
granulocytic MDSCs (not shown). FoxP3-expressing regulatory T cells (Treg 
cells) have been shown to be induced by and mediate the 
immunosuppressive activity of MDSCs (18). Both monocytic and granulocytic 
myeloid populations   significantly enhanced the formation of Tregs 
(CD4+/CD25+/Foxp3+) when mixed with total CD3+ splenocytes. Pre-
treatment with Polyphenon E significantly impaired the ability of myeloid cells 
to induce Treg cells, further suggesting that green tea catechins negatively 
modulate the immunosuppressive function of myeloid cells (figure 5b). 
Interestingly, incubation with Polyphenon E reduced Arginase-1 expression in 
8 out of 10 bone marrow cell preparations cultured for 4 days in the presence 
of neuroblastoma supernatants (figure 5c), indicating that the formulation also 
negatively modulates a gene critically required for the immunosuppressive 
function of MDSCs (19). 
 
Myeloid cells with immunosuppressive activity are found in the blood and 
metastatic tumour of neuroblastoma patients 
It is still unknown whether MDSCs-like cells are induced in neuroblastoma 
patients. The CD66b antigen is one of several markers present on the surface 
of MDSCs in tumour bearing patients (20, 21), and we first determined that 
cells expressing MDSC markers, including CD66b, are increased in the blood 
of neuroblastoma patients, in comparison to age-matched controls 
(supplementary table 1). We had sufficient blood sample for detailed 
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functional analysis in one patient who had an increased number of CD66b 
positive cells, compared to a healthy control (figure 6a). Stimulation of PBMC 
(peripheral blood mononuclear cells) with beads linked to CD3/CD28 
antibodies, induced proliferation of control, but not patient, T lymphocytes. 
Interestingly, depletion of CD66b cells increased the proliferation of patient’s 
CD4 and CD8 T cells (figure 6b), indicating that myeloid cells bearing this 
marker possess immunosuppressive activity. To verify the potential role of 
tumour-infiltrating MDSCs in neuroblastoma, leucocytes were isolated from a 
metastasis of another patient. A large number of cells from the disaggregated 
tumour were positive for the myeloid markers CD11b, CD66b, CD68 and 
CD33 (figure S7).  Leukocytes isolated by Ficoll centrifugation were then 
incubated with beads bearing an anti-CD3/CD28 antibody to activate tumour-
infiltrating lymphocytes, in the presence or absence of Polyphenon E. After 5 
days in culture, there was a 3 fold increase in the percentage of CD8 T cells in 
the presence of Polyphenon E, but not when myeloid cells were depleted 
using beads linked to a CD66b antibody (figure 6c). Furthermore, incubation 
with Polyphenon E increased the incorporation of 3-[H]-thymidine with respect 
to vehicle treated cells, suggesting that the green tea formulation stimulated 
the proliferation of tumour-infiltrating CD3+lymphocytes. The pro-proliferative 
effects of Polyphenon E were abrogated after cell depletion by beads linked to 
a CD66b antibody (figure 6d).  
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Discussion  
 
Myeloid suppressor cells, or MDSCs, are myelo-monocytic cells with 
immunosuppressive activity induced by tumour growth. These cells have been 
thoroughly characterised in the mouse and are distinguished in granulocytic 
and monocytic MDSCs, according to the presence of specific markers: 
monocytic MDSCs are CD11b+ve/Ly6G-ve/Ly6Chigh, whereas granulocytic 
MDSCs are CD11b+ve/Ly6G+ve/Ly6Clow. There are no uniform markers for 
human MDSCs, although it has been observed that lineage-negative (Lin-) 
myeloid cells bearing Cd11b, CD33 and various combinations of CD66b, 
CD14, CD15, HLA-DRlow markers have immunosuppressive activity (22). 
Pharmacologically-induced differentiation, or depletion of these cells have 
been shown to improve the immune response in cancer patients (23, 24). 
Thus, it is likely that therapeutic interventions aimed at the inactivation of 
MDSCs could benefit patients by re-activating the antitumour immune 
response. Neuroblastoma is a paediatric cancer with a dismal outcome in its 
high-risk, metastatic form. The current treatment options are chemotherapy, 
autologous stem cell transplantation, surgery, and radiation therapy. While the 
prognosis of children with localized neuroblastoma is very good, about 40% of 
patients with metastatic, high-risk neuroblastoma succumb to the disease in 
spite of aggressive treatments (25). The heavy chemotherapy regimens result 
in short- and long-term complications, therefore the use of non-toxic drugs 
would be particularly advantageous in this paediatric setting. Polyphenon E is 
a well-defined pharmaceutical grade mixture that contains five different 
catechins used in cancer clinical trials funded by the National Cancer Institute. 
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A total of 15 active or recruiting phase I and II clinical trials with the agent are 
now going on (5). The result of a phase I trial of daily oral Polyphenon E in 
patients with asympthomatic Rai stage 0 to II chronic lymphocytic leukemia 
showed a decline in absolute lymphocytic counts and/or lymphoadenopathy in 
the majority of patients (6). Importantly, the formulation was non-toxic and 
very well tolerated even at very high dosages (6).  More recently, a placebo 
controlled study in prostate cancer patients before prostatectomy showed 
favorable changes in serum prostate specific antigen and a decrease in 
Gleason score between biopsy and surgical specimens in the Polyphenon E 
arm, although the differences were not statistically significant (26).  
In this pre-clinical study using mouse models of neuroblastoma, we have 
shown that Polyphenon E has a significant anti-cancer activity in both 
prophylactic (MYCN model) and therapeutic (AJ model) settings, suggesting 
that the formulation could be potentially used in neuroblastoma children as a 
chemopreventive agent during cancer remission or during therapy in 
combination with chemotherapeutic drugs. Importantly, our study 
demonstrates that the anticancer effect is only significant in the context of a 
functioning immune system and that it occurs via inhibition of MDSCs. 
Another important observation in our study is the drastic increase of 
immunosuppressive cells bearing myeloid markers in a small cohort of 
children with neuroblastoma (supplementary table 1 and figure 6). While this 
finding needs to be confirmed in a larger cohort of patients, to our knowledge 
this is the first documentation of MDSC-like cells in neuroblastoma patients. 
The mechanism by which Polyphenon E disables MDSCs is probably the 
induction of terminal differentiation (figure 4). We show that G-CSF is the key 
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cytokine required to mediate the differentiation activity of Polyphenon E and 
that signalling from the 67kDa laminin receptor is implicated in MDSCs 
maturation. This is a notable finding since the pathways activated downstream 
of this receptor, when identified, could be exploited for therapeutic purposes. 
One important recent advance in the treatment of neuroblastoma has been 
the development of therapeutic antibodies against the GD2 molecule. A 
variety of murine and hybrid murine/human antibodies have been developed, 
and a recent clinical trial has shown a substantial clinical effect of the ch14.18 
antibody (27). Vaccination with GD2 mimotope plasmids or neuroblastoma 
cells transfected with cytokines have also shown promise in mouse models 
(28, 29). From these studies it is clear that cellular mediated cytotoxicity and 
immune regulatory cells are crucially involved in the therapeutic effects of 
immunotherapy. Myeloid cells hamper the function not only of T but also NK 
cells, which are known to be essential for the effect of the ch14.18 antibody 
(30, 31). Furthermore, it is known that tumour induced Tregs blunt the NK and 
CD4/CD8 T cell immune response elicited by different forms of vaccination 
(28, 32). Thus, we hypothesise that the increased numbers of myeloid cells in 
the blood of patients with neuroblastoma could interfere with the antitumour 
immune response and explain the failure of a significant proportion of patients 
to respond to immunotherapy (27). Our observation that Polyphenon E has a 
negative effect on MDSCs and regulatory T cells (Tregs), suggests that the 
formulation could be helpful in the context of neuroblastoma immunotherapy 
and warrants the investigation of the effects of catechins in further clinical 
trials.  
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Figure legends 
 
 
Fig. 1. Polyphenon E prevents tumourigenesis in TH-MYCN mice.  
a) Kaplan Meyer survival curves of mice homozygous for the TH-MYCN 
transgene with (indicated by PE, n=15) or without (indicated by control, n=16) 
0.3% Polyphenon E in the drinking water. b) Trypan blue dye exclusion assay 
to assess killing of primary neuroblastoma cells by Polyphenon E in vitro. 
Primary mouse (from TH-MYCN transgenic mice) neuroblastoma cells were 
cultured in the presence of increasing concentrations of Polyphenon E, as 
indicated. Values in the Y axis indicate percentages of cell death. Error bars 
indicate standard errors. Mock indicates cells in the presence of ethanol 
vehicle; GM indicates cells in growth medium. c) 1x106 SHSY5Y cells were 
injected in the flanks of SCID mice. Mice were randomized in two groups of 10 
mice each, one of which had Polyphenon E in the drinking water for the 
duration of the experiment (4 weeks). d)  Immunofluorescence analysis of 
tumour sections from TH-MYCN transgenic mice, treated or untreated with 
Polyphenon E, showing the presence of infiltrating myeloid cells positive to 
the markers CD11b (red) or Gr-1 (green). The quantification of the experiment 
showed in the graphs on the right. Asterisks indicate that the difference 
observed was statistically significant (CD11b p<0.04 and Gr-1 p<0.05).  
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Fig. 2. Polyphenon E suppresses tumour growth in a therapeutic model of 
neuroblastoma. 
a) A/J mice were randomised in control and Polyphenon E drinking groups (6 
mice each group) and injected in both flanks with 1x106 Neuro 2A cells. After 
3 weeks, tumours were excised and weighed. Control tumours were 
significantly larger than those excised from Polyphenon E drinking mice. * 
indicates statistical significance (p=0.024). b) Quantification of CD11b/GR-1 
double positive, MDSCs-like cells in the organs of control or Polyphenon E 
(PE) drinking, tumour injected mice. Standard errors are indicated by the error 
bars and * indicates statistical significance (p=0.005). c) FACS plot showing 
CD4 and CD8 positive lymphocytes infiltrating the neuroblastomas of control 
or Polyphenon E drinking mice. The double positive cells were detected in the 
tumours of all PE drinking mice. The bar plots in the bottom show a significant 
increase of CD4 and double positive CD8/CD4 cells. Error bars indicate 
standard errors, * p=0.045; ** p=0.006. 
 
 
Fig. 3. MDSCs promote neuroblastoma growth in vivo.  
a) 5x105 Neuro 2A cells were injected into both flanks of A/J mice (5 mice 
each group) alone or mixed with the same number (1:1) of naïve or 
Polyphenol E-treated MDSCs (indicated by MDSC PE). Tumour volumes 
were measured at regular intervals with a caliper. Error bars indicate standard 
errors. The difference in tumour growth at day 13 was significant (MDSC vs 
no MDSC p= 0.001; MDSC vs MDSC-PE p= 0.02). b) A/J mice (6 mice per 
group) were injected as described above but subjected to immunodepletion 
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with CD4 or CD8 antibodies. The difference in tumour growth was significant 
in mice with CD8 immunodepletion (day 14, MDSC-PE isotype control vs 
MDSC-PE CD8 antibody p= 0.01).  
 
 
Fig. 4.  Polyphenon E modulates the MDSCs phenotype. 
a) Dot plot showing the percentage of CD11bhigh bone marrow cells with a 
monocytic or granulocytic phenotype developing in neuroblastoma 
conditioned medium in the presence (PE) or absence of Polyphenon E. Each 
dot is representative of a bone marrow preparation deriving from a single 
mouse. The asterisk indicate that the difference is statistically significant 
(p=0.05). b) Differentiation quick staining of bone marrow cells cultured for 4 
days in the presence of neuroblastoma supernatants with or without 
Polyphenon E.  Percentages of immature and differentiated myeloid cells are 
quantified in the bar plot at the bottom of the panel. Error bars indicate 
standard errors. c) Migration of monocytic (LyG-ve/LyChigh) and granulocytic 
(LyG+ve/LyClow) towards neuroblastoma cells. Myeloid cells were placed in 
the inner well of a transwell (Costar) divided from the outer well by a cell 
permeable membrane. Neuroblastoma cells served as attractants and were 
placed in the outer well. Following an incubation period of 3 hrs the cells in the 
inner and outer well were stained with antibodies and enumerated by FACS. 
d) The molecular changes induced by Polyphenon E are blocked by a 67kDa 
laminin receptor antibody. Percentages of cells with a monocytic or 
granulocytic phenotype are i
antibody;  * p=0.04; ** p=0.01  
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Fig. 5. Polyphenon E impairs the immunosuppressive activity of MDSCs. 
a) Interferon-gamma produced by CD3 cells alone (control), mixed with 
monocytic (Ly6C-ve/Ly6G+ve) MDSCs (2:1 ratio) pre-treated with control 
vehicle (MDSC) or Polyphenon E (MDSC+PE). Asterisk indicates statistical 
significance, p=0.001. b) Modulation of Foxp3+ Treg by myeloid cells 
developing in neuroblastoma-conditioned medium. CD11b+ myeloid cells 
bearing the markers indicated on the top of the panel were FACS sorted and 
mixed at a 1:1 ratio with purified CD3+ splenocytes. CD4/CD25/Foxp3 Tregs, 
developed in the presence or absence of myeloid cells pre-treated with 
vehicle (C) or Polyphenon E (PE), were enumerated by flow cytometry. 
Values in the Y axis indicate the fold of Tregs increase over control (i.e. Tregs 
developing in the absence of myeloid cells). * p=0.05; ** p=0.01. c) 
Expression of Arginase-1 is reduced in myeloid cells induced by 
neuroblastoma supernatants treated with Polyphenon E. Reverse 
transcriptase-PCR  analysis was carried out with Arginase-1 (ARG1) or 
Gapdh, as a loading control, primers, using RNAs extracted from bone 
marrow cells prepared from 10 mice cultured in the presence or absence of 
Polyphenon E.  
 
Fig. 6.  MDSC-like cells are found in the blood of neuroblastoma patients and 
Polyphenon E rescues proliferation of infiltrating T cells in human 
neuroblastoma. 
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a) FACS plots showing the percentages of CD66b cells in the PBMC layer of 
a neuroblastoma patient (indicated by NB), before or after column depletion 
(indicated by NB -CD66b), and a normal healthy control (indicated by ctrl). b) 
T cell proliferation assay. PBMC from the neuroblastoma patient or control 
individual were stained with CFSE and cultured for the indicated days in the 
presence of CD3/CD28 beads.  Cells were then stained with CD4 or CD8 
antibodies and subjected to flow cytometry analysis. Percentages of resting T 
cells are indicated in the right side of each FACS plot.  
c) Leukocytes infiltrating a resected tumour were isolated by Ficoll gradient 
and put in contact with beads linked to a CD3/CD28 agonist antibody in the 
presence or absence of Polyphenon E, with our without depletion of myeloid 
cells with beads conjugated to a CD66b antibody. After 4 days, percentages 
of CD4 and CD8 positive cells were scored by FACS analysis.  d) Infiltrating 
leukocytes were stimulated with an agonist CD3/CD28 antibody and 
incubated for 48 hours with 3[H]-thymidine, in the presence (indicated by PE) 
or absence (indicated by CTRL) of Polyphenon E with or without depletion of 
myeloid cells with a CD66b antibody, as indicated in the top of the graph. 
Error bars indicate standard errors.   
 
 
 
 
 
